Immune Checkpoint Blockade

• 6535 6535 Enhancing NSCLC susceptibility to anti-PD-1 - PD-L1 therapy trough PD-L1 ligand-Ir(III) complex conjugates Valentina Pagliara, Giulia Assoni, Giovanna Polcaro, Luigi Liguori, Pierfausto Seneci, Francesco Saverio Di Leva, Vincenzo Maria D’Amore, Cristina R. Ferrone, Stefano Pepe, Luciana Marinelli, Daniela Arosio, Francesco Sabbatino
• 6536 · PDF A novel multi-modal PD-L1xVEGF-ADC, HX116, could be a new potent candidate treatment for pan-solid tumors Hang Ke, Tao Yang, Feiyu Peng, Jialin Li, Cen Chen, Lei Zhang, Faming Zhang, Henry Li
• 6537 · PDF Tumor IDO1 drives resistance to adoptive cell transfer by suppressing T cell recruitment and effector function Mamadou Alpha Bah, Rachana Maniyar, Jonathan F. Khan, Anais Assouvie, Sadna Budhu, Parwiz Abrahimi, Inna Serganova, Gabrielle A. Rizzuto, Taha Merghoub, Jedd D. Wolchok
• 6538 · PDF A phase-separation mechanism underlying PD-1-mediated T-cell inhibition via Shp2 condensation Takeya Masubuchi, George Wen, Xiaoxian Song, Haian Shao, Enfu Hui
• 6539 · PDF Characteristics and predictors of multi-system immune-related adverse events in a large pan-cancer cohort: A retrospective analysis Julia G. Contini, Min Jung Koh, Charmi Trivedi, Mackenzie Adams, Jacqueline J. Chu, Sapana R. Gupta, Curtis Petruzzelli, Kanika Malani, Rebecca Steuer, Sandeep Jain, William Park, May Min, Matthew J. Hadfield
• 6540 · PDF Dissecting mechanisms of tumor immune checkpoint blockade resistance due to host genetic variation within Adam17 James P. Heiserman, Darren Li, Ons Mamai, Tanuja Desai, Rosemary J. Akhurst, Szu-Ying Chen
• 6541 · PDF Time-of-day of first checkpoint inhibitor dose influences clinical outcomes and immune responses in hepatocellular carcinoma Howard L. Li, Soren Charmsaz, Benjamin J. Reisman, Franshisca Hayek, Madelena Brancati, James M. Leatherman, Carlotta Pazzi, Royce P. Lee, Xiyu Zhao, Eric Christenson, Waqar Arif, Jeric P. Hernandez, Caroline Ellis, Nicole E. Gross, Christopher Thoburn, G Scott Chandler, Rajat Mohindra, Sanjay Bansal, Laura Tang, Aditi Guha, Chi V. Dang, Neeha Zaidi, Elizabeth M. Jaffee, Daniel A. Laheru, Daniel J. Zabransky, Marina Baretti, Won Jin Ho, Mark Yarchoan, Mari Nakazawa
• 6542 · PDF Targeting ITGB3 reverses terminal T cell exhaustion to enhance therapeutic efficacy in esophageal squamous cell carcinoma Beilei Liu, Xin-Yuan Guan, Bowen Yao, Hongyu Zhou, Licheng Tan, Jiayi Huang, Shuang Zhang
• 6543 · PDF NTX1088 demonstrates the first-ever clinical restoration of DNAM1, defining a novel immune-oncology axis Anas Atieh, Alon Vitenshtein, Akram Obiedat, Simona Chechik, Rivki Cashman, Guy Cinamon, Keren Paz, Yaron Daniely, Paola Kučan Brlić, Tihana Lenac Roviš, Lea Hiršl, marija mazor, ema bellulovich, Stipan Jonjic, Ofer Mandelboim, Pini Tsukerman
• 6544 · PDF Immune checkpoint inhibitor therapy in kidney transplant recipients: Real-world outcomes of antitumor activity and graft rejection risk Ali Rezazadeh Roudkoli, Elena Barbir, Shahin Kavousi, Mohamed A. Aboelatta, Claudia-Denise Haivas, Byron H. Smith, Aleksandra Kukla, Arkadiusz Z. Dudek
• 6545 · PDF Characterizing ATF6 activation-driven mechanisms improving ICB efficacy Sanjay Adhikary, Jacob Edmondson, Daniel Fil, Duah H. Alkam, Megan R. Reed, Billie Heflin, Katherine Bronson, Sydnye Shuttlewoth, Katherine F. Wallis, Nathan Avaritt, Sean Taverna, Brian S. Koss, Alan Tackett
• 6546 · PDF Beyond density: Topography-aware spatial metrics predict immunotherapy outcomes Artur Mezheyeuski, Neda Hekmati, Ina Hrynchyk, Amanda Lindberg, Jakob Friedrich, Johanna Mattsson, Miklos Gulyas, Klas Kärre, Johan Isaksson, Carina Strell, Patrick Micke
• 6547 · PDF Phase II single arm study of tremelimumab and durvalumab (MEDI4736) (T300+D) in advanced hepatocellular carcinomas with Child-Pugh-B cirrhosis (STRIDE in CP-B) Sukeshi Patel Arora, Lorena Fuentes, James Denno, Jennifer Moseley, Brittany M. Altermatt, Elizabeth Diaz, Joshua Ray Smith, Joel Michalek, Lei Zheng
• 6548 · PDF A human multiorgan microphysiological system for modeling immunotherapies tumor clearance and normal tissue immune injury John Collins, Henry C. Wong, Alyssa J. Villegas, Johar Kohana, Harpreet S. Saluja
• 6549 · PDF Integrating functional biosignatures and same-cell spatial multiomics to predict synergistic benefit of combination checkpoint therapy in head and neck cancer Yi Cui, Moumita Nath, Michael Emilio Patrick, Claire Williams, Daniel McGuire, Jobin K. Paul, Kowshik Jaganathan, Biswajit Das, Mohit Malhotra, Shanshan He, Joseph M. Beechem, Satish Sankaran
• 6550 · PDF In vitro characterization of fully human antagonistic anti-BTLA monoclonal antibodies Bruce L. Daugherty, Hsunhui Yang, Subhra Mahapatra, Yadong Yu, Christine L. Hsieh, Brian A. Zabel, Seth Lederman
• 6551 · PDF Mifepristone-mediated induction of PD-L1 expression in hormone receptor positive breast tumors Mariana Salatino, Magali Berton, Joaquin Merlo, Andres M. Elia, Tomas Dalotto Moreno, Claudia Lanari, Gabriel Rabinovich
• 6552 · PDF Nonresponders to PD-1 therapy share a combined OXPHOS and neuronal-like resistance program in melanoma Otília Menyhart, Janos Tibor Fekete, Balazs Gyorffy
• 6553 6553 A comprehensive analysis of HMGB1 as a biomarker for predicting immunotherapy efficacy in small cell lung cancer Bohui Zhao, Chaoqi Zhang, Peng Wu, Dongyu Li, Xuanyu Gu, Hengjia Tu, Nan Sun, Jie He
• 6554 · PDF A bispecific TROP2/PDL1 antibody-drug conjugate demonstrates enhanced antitumor activity and favorable safety profile Chuan Chen, Yue Wu, Chenpeng Su, Dandan Liu, Jiyuan Tian, Yujuan Li, Yongxin Shang, Xiaoqian Chen, Rongmei Yan, Liang Tian, Jian Peng, Zhenping Zhu
• 6555 · PDF BTN1A1 blockade with Nelmastobart potentiates cisplatin-induced tumor suppression in NSCLC Seung-Hoon Lee, Jong-Su Park, Young-Seung Kim, Chunai Wu, Bong-Ki Hong, Andrew H. Park, Stephen S. Yoo
• 6556 · PDF The role of VISTA in the lung tumor microenvironment of metastatic melanoma Carly M. Fielder, Qianni Hu, Hyundong Yoon, Raymond Zhang, Anjali Raman, Megan L. Tigue, Chi Yan, Vivian L. Weiss, Douglas B. Johnson, Jin Chen, Tae Kon Kim
• 6557 · PDF Combined PARP inhibition and immune checkpoint blockade elicit differentially improved survival in BRCA1, BRCA2 vs CHEK2, ATM deficient breast cancer by promoting an anti-tumor immune response through tertiary lymphoid structure formation Sibapriya Chaudhuri, Alberto Emata, Scott Thomas, Pamela N. Munster
• 6558 · PDF Selenium dependent regulation of immune checkpoint control in acute myeloid leukemia Deborpita Sarkar, Fenghua Qian, Robert F. Paulson, K.Sandeep Prabhu
• 6559 · PDF Investigating the transcriptomic signature of B7-H7-mediated activation of NK cell activity Michael Gomez, Deepthi Chowbene, Nahuel Perrot, Nikolaos Kalavros, Shuoshuo Wang, Antonella Arruda de amaral, David F. McDermott, Gordon J. Freeman, Ioannis S. Vlachos, Kathleen M. Mahoney
• 6560 6560 Targeting fitness surveillance restores T-cell immunity and sensitizes solid tumors to immune checkpoint inhibitors Amit Kumar, Antonio Palma, Praveen Bhoopathi, Esha Madan, Rajan Gogna
• 6561 · PDF Rational design of a B7-H3/PD-L1 bsADC combining checkpoint blockade with targeted cytotoxicity for improved antitumor efficacy Zhangyi Song, Jie Chen, Huifang Zong, Zhen Li, Shusheng Wang, Jianwei Zhu, Xiaodong Xiao
• 6562 · PDF Identifying vulnerabilities to immune checkpoint inhibitors of oncogene-addicted non-small cell lung cancer subgroups. Inés Díaz-Cano, José Gracia, Patricia Cozar, Belén Revuelta, Nuria Carrizo, Laura García-Redondo, Joan Russo, Rita Manzano, Jose Garrido-Mesa, Daniel Meraviglia-Crivelli, Juan Dubrot, Luis Paz-Ares, Itziar Otano
• 6563 · PDF Immune and clinical determinants of response to immune checkpoint blockade (ICB) rechallenge after perioperative chemoImmunotherapy in gastroesophageal cancer Jeremy M. Tchack, Samuel L. Cytryn, Steven B. Maron, Patrick Evans, Jessica Posada, Geoffrey Y. Ku, Jessica Yang, Ryan B. Sugarman, Ping Gu, Laura H. Tang, Amitabh Srivastava, Vivian E. Strong, Daniela Molena, Yelena Yuriy Janjigian
• 6564 · PDF Spatially resolved immunologic hallmarks of response to neoadjuvant immune checkpoint blockade in metastatic melanoma Zichao Liu, Xiaofei (Sophia) Song, Jodi A. Balasi, Wei-Shen Chen, Jiang He, Justin He, Jonathan Nguyen, Carlos M. Morán-Segura, Joseph O. Johnson, Chaomei Zhang, Jane L. Messina, Zena Sayegh, Douglas C. Marchion, Sean J. Yoder, Vernon K. Sondak, Jeffrey H. Chuang, Pei-Ling Chen

在会议检索中浏览本分会场